## CLAIMS

1. Use of a pharmaceutically acceptable acid addition salt of:

(i) S-pindolol; and

(ii) an organic acid,

for the manufacture of a medicament for the treatment or prevention of cachexia,

wherein the organic acid is benzoic acid or succinic acid.

2. Use according to claim 1, wherein the pharmaceutically acceptable acid addition salt is crystalline.

3. Use according to claim 1 or claim 2, wherein the pharmaceutically acceptable acid salt is in the form of a solvate.

4. Use according to any one of the preceding claims, wherein the organic acid is benzoic acid.

5. Use according to any one of the preceding claims, wherein the salt is S-pindolol benzoate.

6. Use according to claim 5, wherein the S-pindolol benzoate is S-pindolol monobenzoate.

7. Use according to claim 5 or 6, wherein the S-pindolol benzoate is in the form of S-pindolol benzoate crystalline polymorph Pattern 1 having an x-ray powder diffraction pattern comprising peaks at 8.1°, 11.4° and 17.0° ± 0.2° 2θ.

8. Use according to claim 7, wherein the x-ray powder diffraction pattern further comprises peaks at 5.7°, 12.5° and 18.4° ± 0.2° 2θ.

9. Use according to claim 5 or 6, wherein the S-pindolol benzoate is in the form of S-pindolol benzoate crystalline polymorph Pattern 2 having an x-ray powder diffraction pattern comprising peaks at 16.9°, 18.9° and 20.1° ± 0.2° 2θ.

10. Use according to claim 9, wherein the x-ray powder diffraction pattern further comprises peaks at 9.2°, 13.9° and 20.7° ± 0.2° 2θ.

11. Use according to any one of claims 1 to 3, wherein the salt is S-pindolol succinate.

12. Use according to claim 11, wherein the S-pindolol succinate is S-pindolol monosuccinate.

13. Use according to claim 11 or 12, wherein the S-pindolol succinate is in the form of S-pindolol succinate crystalline polymorph Pattern 1 having an x-ray powder diffraction pattern comprising peaks at 13.3°, 16.7° and 19.5° ± 0.2° 2θ.

14. Use according to claim 13, wherein the x-ray powder diffraction pattern further comprises peaks at 8.3°, 12.2° and 12.8° ± 0.2° 2θ.

15. Use of a composition comprising at least 60 wt% of a pharmaceutically acceptable acid addition salt as defined in any one of the preceding claims relative to the total weight of the composition in the manufacture of a medicament for the treatment or prevention of cachexia.

16. Use according to claim 15, wherein the composition comprises no more than 30 wt% of R-pindolol or a salt thereof relative to the total weight of the composition.

17. Use of a pharmaceutical composition comprising (i) a pharmaceutically acceptable acid addition salt as defined in any one of claims 1 to 14 and (ii) a pharmaceutically acceptable excipient, carrier or diluent in the manufacture of a medicament for the treatment or prevention of cachexia.

18. Use according to claim 17, wherein the pharmaceutical composition is a tablet.

19. Use according to claim 17 or 18, wherein the composition is substantially free of R-pindolol or a salt thereof.